Keyword: Bill Sibold

With PCSK9 cholesterol drug Praluent ramping up more slowly than expected, Sanofi and Regeneron plan a new investment in blockbuster hopeful Dupixent.

Could Dupixent end up beating Novartis’ Cosentyx on launch trajectory? The numbers are looking that way so far, a Sanofi executive said Monday.

Three months ago, England’s cost watchdogs nixed Sanofi's Gaucher treatment Cerdelga. But they're already singing a different tune.

As Sanofi's Genzyme unit gears up for a blockbuster Dupixent launch, CEO David Meeker is making an exit, with insider Bill Sibold taking his place.